Recent Advances of Pharmaceutical Process Chemistry and Its Innovation in China: Part 1

Pei Tang¹  Biao Nie²  Jiuzhong Huang²  Yingjun Zhang²,³  Ji Zhang²,³  Fen-er Chen¹,⁴

¹ Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China
² HEC Pharm Group, HEC R&D Center, Guangdong, People’s Republic of China
³ The State Key Laboratory of Anti-Infective Drug Development, Guangdong, People’s Republic of China
⁴ Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, People’s Republic of China

Address for correspondence: Fen-er Chen, PhD, Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, 220 Handan Road, Shanghai, 200433, People’s Republic of China (e-mail: rfchen@fudan.edu.cn).

Ji Zhang, PhD, The State Key Laboratory of Anti-Infective Drug Development, Guangdong, 523871, People’s Republic of China (e-mail: zhangji@hecpharm.com).


Abstract

This review article summarizes recent developments and innovations in China’s pharmaceutical process chemistry over the last several decades. Case studies of dozens of blockbuster drug processes are presented, including bulk drugs, such as the over-the-counter medicine biotin, demonstrating China’s substantial effort to green its pharmaceutical processes. Owing to the increasing stringent environmental regulations, Chinese chemists have invented several cutting-edge and eco-friendly synthetic methods that are beneficial to environmental protection. Applied to large-scale industrial production, these processes have a greatly reduced environmental footprint, promoting the sustainable development of global economy and health.

Keywords

- pharmaceutical industry
- green process
- asymmetric catalysis
- chiral drugs
- stereoselectivity

Introduction

With the rapid improvement in China’s modern industry and the Chinese people’s standard of living over the past decades, China has become a major player in pharmaceutical production. China is also a country experiencing a rapid increase in its aging population, which has coincided with the massive consumption of medicine. The needs of basic chemical and pharmaceutical industries have solid foundations. According to recent statistics,¹ in 2017, there were more than 2,000 pharmaceutical companies in China producing active pharmaceutical ingredients (APIs). These companies are collectively producing 1,600 various kinds of APIs with a total production capacity of 3.478 million tons, of which exports exceeded 1 million tons at a value of nearly 210 billion RMB (Chinese yuan). Both drug production capacity and export scale ranked No. 1 in the world. In the meantime, the size of the Chinese API market reached 573.5 billion RMB in 2017, and the market of pharmaceutical intermediates achieved 430 billion RMB.

Fig. 1 shows the sales revenue of China’s APIs from 2010 to 2017. Therefore, it is very important to develop a sustainable Chinese pharmaceutical industry that is beneficial not only to the Chinese people, but also to the world.

Several major reasons have prompted the Chinese pharmaceutical industry and academic laboratories to explore, innovate, and develop novel green technologies in pharmaceutical processes. First, the Chinese government has introduced stricter environmental protection regulations in recent years, incentivizing pharmaceutical companies to upgrade their technology and to employ green synthetic methods and processes. Second, the government-led procurement policy has moderated drug prices to a reasonably low point, which has been a driving force for reducing drug production costs. Third, Chinese pharmaceutical companies want to survive in a competitive market, requiring the development of much greener and safer operations. Finally, a series of safety-related accidents have also educated the Chinese society and urged the need for state-of-
the-art and safe processes. At the same time, China wants its APIs to be competitive in the international market by lowering production costs and improving quality, while also minimizing the impact on the environment to preserve China’s abundant natural resources.

Therefore, by applying the guiding principles of green chemistry,2 and learning from the successes of multinational pharmaceutical companies in the United States, and Europe,3–5 Chinese academics and pharmaceutical chemists have initiated the exploration and innovation of green pharmaceutical processes since the turn of the 21st century. Chinese chemists have also vigorously developed their own revolutionary synthetic processes and have achieved some outstanding innovative processes for drug production based on the economic rationality and continuous availability of the starting materials. Herein, we review the recent progress of the pharmaceutical processes in China over the past decades, but some selected examples may not be comprehensive and lacking in details due to the protection of their intellectual properties.

**Specific Examples and Related Innovation of Industrialized Application of Green Pharmaceuticals**

**Ongoing Pursuit of Practical Biotin Process**

Biotin 1 (►Fig. 2), a water-soluble B series vitamin, was first isolated from egg yolk in 1936.6 It distributes widely in microorganisms, plants, and animals, and plays crucial roles as a coenzyme in the metabolism of fatty acids, sugars, and α-amino acids.7

The chemical synthesis of biotin was accomplished with the first total synthesis of racemic biotin and subsequent optical resolution by Harris et al from Merck in 1943.8 Subsequently, Goldberg and Sternbach at Hoffmann-La Roche applied for patents on the first commercially applicable biotin synthesis in 1946.9 As shown in Scheme 1, the cyclic anhydride 3 was synthesized from commercially available fumaric acid (2), and could be converted into the racemic sulfonium salt 4 after several functional group transformations. Subsequent optical resolution of 4 by the use of camphorsulfonic acid and two additional operations smoothly delivered biotin. Since these pioneering works, the synthesis of biotin has long challenged industrial and academic chemists, and continued to stimulate interest in developing an optimum synthetic approach toward this legendary molecule.7 In 1970, Gerecke and coworkers at Hoffmann-La Roche significantly improved the original Goldberg–Sternbach approach,10 which featured a ring opening of the cyclic anhydride 3 to a racemic mixture of hemiester 5 by alcoholysis, and the following resolution was realized via the crystalline ephedrine salt of the diastereomeric hemiester. Subsequent reduction/cyclization sequence delivered chiral lactone 6, which could then be built up in several steps into biotin via thiation/Grignard/homologation sequence. It is worth noting that this procedure was operated on a commercial scale by Roche until the 1990s, and lactone 6 has been the most commonly utilized chiral intermediate in the processes delivering biotin.7

In 2001, Chen, one of the authors of this article, developed an improved resolution route for the synthesis of chiral Roche’s lactone 6 at Fudan University (Scheme 2).11 Central
in the synthesis was the replacement of the ephedrine with chloramphenicol base 8 as the resolving agent, providing the desired enantioenriched half-ester 9 in 37% yield, which was comparable to the yield obtained via Roche’s approach.

An impressive development of efficient asymmetric strategies—that is, the direct conversion of cyclic meso-anhydride 3 to optically active lactone 6—was realized by Matsuki et al in 1993. Employing (R)-BINAL-H (11), the asymmetric reduction of 3 delivered 6 in 76% yield and 90% ee. Subsequently, this transformation was further extended by Chen et al to a method utilizing thiocarboxylic anhydride 10, which was readily synthesized from anhydride 3 via thiation (Scheme 3). Reaction of 10 in the presence of (R)-BINAL-H (11) smoothly afforded thiolactone 12 in a higher efficiency with 83% yield and 98.5% ee. Enantioenriched 12 could then be built up in several steps into biotin. Moreover, the plausible mechanism of this enantioselective transformation was proposed by Chen, as illustrated in Scheme 3, and the Si-face of the carbonyl group should be selectively reduced by means of a favorable n–π* interaction between the oxygen nonbonding orbital and the lowest unoccupied molecular orbital (LUMO) of the thioanhydride moiety.

In 1999, Shimizu et al reported the enantioselective reduction of meso-N-benzyl imide 13 into the corresponding chiral hydroxylactam 14 with borane in the presence of an oxazaborolidine catalyst derived from L-threonine. Despite a 98% ee, the yield of 14 was moderate (65%). Indeed, this asymmetric CBS (Corey-Bakshi-Shibata)-type reduction has been studied extensively by Chen and coworkers (Scheme 4). With in situ generated borane from cheap, safe, and convenient lithium hydride/sodium hydride and boron trifluoride etherate, they prepared three types of oxazaborolidine catalysts, chloramphenicol base derivative 15, polymer-supported sulfonamide 16, and polymer-supported amino alcohol 17. Treatment of imide 13 with these chiral oxazaborolidines provided hydroxylactam 14 in
excellent outcome of yields and enantioselectivities (82–91% yield, ≥98% ee). The latter underwent further reduction and acid treatment, leading to lactone 6 in 92% yield, which could readily be converted into biotin through thiation and the subsequent introduction of a C5 side chain using modified di-Grignard approach, with 1,4-dibromobutane and carbon dioxide as the reactants. Thus, this route would be greatly beneficial to the scalable synthesis of biotin.

The enantioselective alcoholysis of meso-cyclic anhydrides is a powerful strategy to conveniently access optically active hemiesters as valuable building blocks for many natural products and biologically active substances. In particular, Deng, Song, Bolm, and their coworkers have made numerous impressive progresses in the opening of anhydrides by chiral Lewis bases, as demonstrated by cinchona alkaloids and their derivatives. Toward ongoing pursuit of asymmetric synthesis of biotin, Chen and coworkers developed a novel organocatalytic anhydride desymmetrization strategy (Scheme 5). In this pivotal transformation, two contiguous stereogenic centers were readily established through a rapid chloramphenicol base and cinchona alkaloid catalyzed enantioselective alcoholysis of meso-cyclic anhydride 3 to afford hemiesters 18, with excellent yields and enantiomeric excesses (up to 99% yield, 98.5% ee). Conversion of hemiesters 18 to biotin was readily achieved via a well-known process. Given such high efficiency of the desymmetrization, Chen developed an asymmetric alcoholysis strategy that has great potential for use in the mass production of biotin.

After unremitting efforts and continuous innovation, Chen successfully solved several critical bottleneck reaction problems and key transformations, and developed four new cutting-edge and eco-friendly technologies and processes for the biotin synthesis, including chemical resolution, asymmetric reduction, and asymmetric alcoholysis processes. Indeed, Chen’s synthetic methods represent a major breakthrough in...
the industrial production of biotin.\textsuperscript{23} Notably, triggered by the endeavors of asymmetric synthesis of biotin, Chen has conducted a deep and extensive research on chloramphenicol base chemistry for decades, achieving a series of significant progresses involving chiral catalysts, chiral auxiliaries, synthetic methodologies, and total synthesis.\textsuperscript{24,25}

**Revolutionary Artificial Synthesis of Artemisinin**

Each year, hundreds of millions of people are infected with malaria around the world. In 2010 alone, the number of infected people was as high as 200 million, and the number of deaths was as high as 655,000. According to the World Health Organization (WHO), approximately 40\% of world’s population is threatened by malaria. Every year, an estimated 350 to 500 million people are infected with malaria, and 3,000 children die every day because of it.\textsuperscript{26}

Artemisinin is a natural ingredient used in the effective treatment of malaria. After a team of Chinese scientists successfully extracted it from plants in the 1970s, the development of related drugs was performed. In 2005, artemisinin-based combination therapy was recommended by the WHO as the best way to treat malaria.\textsuperscript{27} It is of great medical, economic, and social significance to solve the problem of raw materials for artemisinin production. However, artemisinin antimalarials are in short supply. The international market for artemisinin is approximately 180 tons. Even so, there are still many people who need it for the treatment.

Artemisinin is a kind of terpenoid compound, originally extracted from the plant *Artemisia annua* (*Fig. 3*). The main domestic production method is still extraction from *A. annua*, but the plant occupies cultivated land and depends on the environment. The production of artemisinin is mainly performed by repeatedly extracting *A. annua* L. with an organic solvent and purifying and separating it. Among the steps, the leaching step has problems of low selectivity and serious solvent loss, and the purification and separation processes (*Fig. 4*) have long processing times and high energy consumption, resulting in limited processing capacity and limited production capacity. Furthermore, the extraction process is cumbersome.

At present, the production of artemisinin still relies mostly on plant extraction. Seventy percent of artemisinin raw materials come from China. In 2006, scientists from Amyris Inc. and the University of California, Berkeley, United States, developed a biological process using engineered yeast for the production of large quantities of artemisinic acid \textsuperscript{20} (AA; Scheme 6).\textsuperscript{28}
thus, the two remaining challenges are how to convert AA into dihydroartemisinic acid (DHAA) and DHAA into artemisinin.

The transformation of artemisinic acid into artemisinin antimalarials is also far from simple. Artemisinin is a sesquiterpene lactone compound containing a peroxy group. The rare peroxygen is fixed and connected with two quaternary carbon atoms, forming a bridge. The full synthesis of this peculiar structure is extremely challenging.\(^{29}\)

In 2011, Wu and colleagues reported the synthesis of artemisinin in the absence of light from artemisinic acid.\(^{30}\) The process was performed at room temperature to obtain artemisinin in a total yield of 41\% in 2013, using an improved synthetic technology (Scheme 7).\(^{31}\)

The research team led by Zhang, at the School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University (SJTU), finally developed a conventional and practical asymmetric hydrogenation synthesis method for (R)-DHAA 21 (Scheme 8), a key intermediate for artemisinin.\(^{32}\)

In 2005, Zhang led a team that converted artemisinic acid into (R)-DHAA 21, and then used a specific catalyst they developed to allow efficient production of DHAA through a conventional reaction device without a photochemical reaction, which is often less effective. Finally, artemisinin was obtained in high yield by oxidative rearrangement. In 2012, they developed a chemical synthesis method that does not require the use of light to further increase the synthesis efficiency of artemisinin. This was a major advance made by Chinese scientists in the field of high-efficiency synthesis of artemisinin, which will make large-scale production of artemisinin a reality (Scheme 9).\(^{33}\)

From 2012 to 2016, Zhang and coworkers worked diligently to industrialize this technology. They achieved a
smooth 30- to 500-L (multikilogram) scale-up or pilot synthesis, making a low-cost artemisinin supply a reality. For the first time, the high-efficiency synthesis of the antimalarial drug artemisinin was made possible, and artemisinin is expected to achieve large-scale industrial production by Shanghai Fosun Pharmaceutical (Group).

**Scalable Total Synthesis of Antitumor Marine Nature Product Trabectedin (ET-743)**

The first marketed modern marine drug for the treatment of soft tissue sarcoma was trabectedin 31 (ET-743). Its analogues are undergoing phase III clinical studies for the treatment of small-cell lung cancers. Current production requires the use of another rare natural product, tunicate, which can only generate 1.0 g of ET-743 from 1.0 ton of tunicate via semisynthesis, requiring 21 steps of reaction with only 1% total yield. The market price of the drug substance is >$10,000/g. Over the past 20 years, four routes have been developed for the total synthesis of ET-743 from readily available raw materials, but the total number of steps for each route is all above 40, contributing to their low overall yield and preventing scale-up for industrial production.

In 2019, Ma and coworkers at Shanghai Institute of Organic Chemistry (SIOC) developed a novel, highly efficient, and practical total synthesis method of ET-743 from Cbz-protected (S)-tyrosine. This new synthetic method delivers a 1.6% overall yield in 26 total steps, with a light-mediated remote C–H bond activation to assemble a benzo[1,3]dioxole-containing intermediate 27 (Scheme 10). This new method is one-third shorter than the original synthetic route and can be conveniently scaled up. The process and related technologies have been licensed and transferred to a Chinese pharmaceutical company and will make a positive contribution to cancer therapy.

**Cu(I)/Oxalic Diamide Catalyzed Coupling Reaction and Its Application in Pharmaceutical Processes**

Ma and coworkers at SIOC first developed the amino acid-promoted Ullmann coupling reaction, a reaction that has been applied thousands of times in the synthesis and development of functional molecules (Scheme 11). The application includes a ton-scale production for the antihypertensive drug perindopril (Scheme 12), intermediates by DSM and tons of production for Xiidra (Lifitegrast) (Scheme 13), a treatment of signs and symptoms of dry-eye disease by Shire,
Scheme 10 Scalable total synthesis of antitumor marine nature product trabectedin (ET-743).

Scheme 11 Ma’s amino acid-promoted Ullmann coupling reaction.

Scheme 12 Ton-scale production of intermediates for perindopril.

Scheme 13 Tons-scale production of Xiidra (Lifitegrast) under Ma’s conditions.
and two other drug candidates 48,45 at phase II clinical trials for the prevention of heart attack, and 53,46 at phase II clinical trials for the treatment of anxiety (Scheme 14).

Aryl sulfone has been one of the top five most frequently used scaffolds in drug structures based on statistics of approximately 7,000 Food and Drug Administration (FDA)-approved drugs and experimental drugs. The classical method for preparing aryl sulfones is the direct sulfonylation of arenes, and in the late stage of manipulation it gives unsatisfactory regioselectivity and poor functional group tolerance. Ma’s amide ligand 55, HMNPC, derived from 4-hydroxy-L-proline and 2-methylnaphthalen-1-amine, is an excellent and highly practical ligand for CuI-catalyzed direct coupling of (hetero)aryl halides with sulfinic acid salts under mild conditions.47 The reaction proceeds at room temperature with only 0.5 mol% CuI and the ligand, representing the first example for Cu-catalyzed arylation with a low catalytic loading under room temperature conditions (Scheme 15).

For the first time in 2015, Ma and coworkers discovered a much more effective oxalyl diamine ligand which achieved a copper-catalyzed coupling reaction of an inexpensive aryl chloro compound under mild conditions,48 coupling aryl bromide and iodide with very low catalyst loading (Scheme 16). Under these milder and more practical conditions, this useful method is expected to be applied to a large-scale production, and more than 10 different APIs and bulk drugs or key intermediates have been prepared or are under preparation by a joint venture in China using this technology (CE PHARM).

It is undeniable that, over the past three decades, palladium-catalyzed C–C cross-coupling reactions, e.g., Suzuki coupling, Negishi coupling, the Heck reaction, and Pd-catalyzed C–N, C–O, and C–S formations, have changed synthetic organic chemistry dramatically. However, from the perspective of economic and sustainable development, under the same circumstances, if a cheaper copper catalyst is capable of carrying out similar transformation yielding comparable experimental results while avoiding harsh experimental conditions, process chemists will prefer to use the copper-catalyzed reactions. The competition between copper and palladium over the past two decades can be traced to a new systematic study of Cu/oxalic diamide ligands (from 2013 to 2018; ► Fig. 5), and copper-catalyzed coupling reactions will find broader applications at academic laboratories and in the pharmaceutical industry.

Chiral Bicycle Imidazole Nucleophilic Catalyst (R-DPI) for Biologically Active Protiide Prodrugs

In 2017, DiRocco and coworkers at Merck, United States, published their latest research on stereoselective phosphorylation49 for the high-efficiency synthesis of the phase III clinical new nucleoside prodrug 63, MK-3682 (Scheme 17). Their work is based on the original work of Zhang on chiral

Scheme 14 Synthesized drug candidates via the amino acid-promoted Ullmann coupling.

Scheme 15 Cul-catalyzed direct coupling of (hetero)aryl halides with sulfinic acid salts.
Scheme 16 Highly effective oxalyl diamine ligand/copper-catalyzed coupling reaction of aryl chloro compounds.

Scheme 17 Chiral imidazole catalyst (R-DPI) for proctide prodrug MK-3682.

Fig. 5 Cu versus Pd, a 20-year competition in catalyzing C–X coupling.
bicyclic imidazole framework catalysts in which he designed and synthesized a multifunctional catalyst with a chiral bicyclic imidazole skeleton, which achieved asymmetric synthesis of nucleoside with high stereoselectivity and high yield. Compared with the existing small-molecule catalysts, the chiral bicyclic imidazole catalyst skeleton introduced by Zhang's team can be constructed in high yield via a one-step reaction of inexpensive imidazole and acrolein, which can be easily prepared on a large industrial scale (Scheme 18).52

Chiral Catalysts for Asymmetric Synthesis of Silodosin, (S)-Duloxetine, and Bulk Drugs

In China, research on asymmetric synthesis of chiral molecules has seen significant improvement in the past decade, with the achievement of excellent research results; however, their application in the pharmaceutical industry still needs development. First, the main limitation of catalytic chiral technology is the turnover number of the catalyst. Generally speaking, catalysts with a turnover number of more than 10,000 in the laboratory are valued for further industrialization. Second, a secondary limitation on catalytic chiral technology in industry is its strict reaction conditions, which cannot be too harsh and must be suitable for industrial use. Third, the requirements for the scale-up or production using this technology must be safe and environmentally friendly. Fourth, the cost of the catalyst cannot be too high. Finally, the pharmaceutical company's own R&D unit and process optimization capabilities should be able to adopt and utilize the new technology, which has also been a key issue.

In asymmetric catalysis studies, chiral phosphorus ligands have been widely used, and many highly efficient chiral phosphorus ligands have been reported. However, since a chiral ligand or chiral catalyst is usually only effective for one reaction or one type of substrate, there are still many chiral compounds that lack effective enantioselective synthesis methods. Therefore, the development of new and effective chiral ligands and catalysts is still one of the central tasks of asymmetric catalysis research. In his research, Zhou of Nankai University found that the chiral spirobiindane structure is an ideal chiral skeleton. It has strong structural rigidity and a stable configuration. The series of chiral ligands (Scheme 19) derived from the skeleton have been widely used in metal catalysis and organic small-molecule catalysis.57

By using the novel Ir-SIPHOX catalyst (Scheme 20), process chemists at Zhejiang Jiuzhou Pharmaceutical accomplished the first asymmetric synthesis of silodosin with high efficiency (S/C = 6,000) and high enantiomeric excess (97% ee) via a new approach in which the key transformation is the asymmetric hydrogenation of an unsaturated carboxylic acid intermediate.58

Using the electron-donating and rigid P-stereogenic bisphospholane ligand DuanPhos, Zhang at Chiral Quest developed a concise process for the preparation of (S)-duloxetine 89, and asymmetric hydrogenation generated chiral alcohol 88 with excellent results (S/C = 10,000, >99% ee), reducing the total cost by 74% and wastewater by 84% compared with its original route (Scheme 21).59 Founded in 2008 and utilizing Zhang's chiral catalysts, Chiral Quest has developed more than 20 new process routes in scale-up, generating hundreds of tons of pharmaceutical intermediates for (S)-duloxetine (for treatment of major depressive disorder), Ramipril (for hypertension), Sitagliptin (for diabetes), and commodity chiral 3-amino-1-butanol (50 tons/year).

Eco-Friendly Process for Praziquantel

Praziquantel is an antiparasitic drug developed in 1980 by Bayer and Merck KGaA. Since its introduction, praziquantel has become a special drug against various worms such as schistosomes due to its high efficiency, low toxicity, wide antiparasitic spectrum, and convenient oral administration. It is also widely used in the treatment of parasitic diseases in animals. The synthetic route of praziquantel reported by the original company is shown in Scheme 22.60

The route used isoquinoline 90 as a starting material, reacting it with benzoyl chloride and potassium cyanide to obtain compound 92, and then compound 93 by high-
pressure (150 atm) hydrogenation reduction. Compound 96 is produced in two steps, and then concentrated phosphoric acid is used to convert it to 97, before it is finally reacted with benzoyl chloride to obtain the target compound. For decades, praziquantel bulk drug manufacturers have adopted this approach. However, Zhang realized that there are many shortcomings in this process route, such as the use of a large amount of...
highly toxic potassium cyanide, as well as high-temperature and -pressure (150 atm) conditions. In addition, the use of concentrated phosphoric acid inevitably leads to eutrophic water pollution. According to statistics, for every 500 tons of praziquantel produced, 310 tons of potassium cyanide are used, and phosphoric acid waste liquid reaches up to 2,430 tons (Fig. 6). This obviously cannot meet the current environmental protection policy requirements and does not conform to green chemistry principles. In response to these problems, Zhang and his team invented the production process of praziquantel via a well-designed and novel synthetic route, as shown in Scheme 23.

The new route successfully avoids the extensive use of highly toxic potassium cyanide and phosphoric acid, and cleverly bypasses high-temperature and -pressure conditions. The new process not only drastically reduces the generation of large amounts of waste, but also reduces production costs to half of that of the original process. The new route has achieved a production scale of 100 tons.

Effective Preparation of Active Pharmaceutical Ingredients and Key Intermediates

In recent years, the use of enzymes and biocatalytic reactions to carry out pharmaceutical processes in industry has become a very important direction for greening scaled-up reactions. The chiral intermediate (3R)-3-aminoazepane is a key motif in the bacterial conjunctivitis antibiotic besifloxacin and in the antitumor clinical drug nazartinib, an estimated glomerular filtration rate (EGFR) antagonist. According to retrosynthetic analysis, the intermediate (3R)-3-aminoazepane 106 is the key raw material for the synthesis of both drugs. Although there are three known synthetic methods (Scheme 24), they face some shortcomings and flaws. Method A uses nonnatural amino acids as raw materials, requires low-temperature operation, and lactamization results in serious racemization. On the other hand, the final amide reduction on scale is very challenging and difficult, and safe production and reduced environmental pollution are not guaranteed. The starting material used in method B is expensive and sodium azide is
Fig. 6  The footprint when 500 tons of praziquantel is produced.

Scheme 23  Novel production process for praziquantel.

Scheme 24  Three known synthetic methods for (3R)-3-aminoazepane.
used, and a large amount of isomer impurities (racemic) are generated, which are neither safe nor economical. The starting material of method C is expensive, which involves the reduction and protection of carboxylic acid and deprotection, and thus is not a good method in view of green chemistry principles.

Process chemists at HEC found that the above synthetic methods are not ideal, and a better method of preparing 106 is by enzyme or biocatalytic transformation. Although at least six synthetic routes are known, there are several disadvantages, among which are the high price of starting materials, the use of precious metal catalysts, unconventional chemical operation, and low overall yields (Scheme 25).

After careful consideration, HEC chemists finally developed a new route that uses commercially available piperidin-2-one 117 as a starting material to access the target molecule effectively in seven steps (Scheme 26). (3R)-3-Aminoazepane 106 is prepared with 46.2% overall yield, 99.92% purity, and 99.2% ee. The practical enzymatic reaction catalyzed by transaminase is a key transformation. This new route avoids the use of expensive metal catalysts or chromatography. It is worth mentioning that the careful choice and optimization of the Dieckmann condensation reaction is a clever use of the telescoping process that avoids unnecessary separation and purification, while, at the same time, turning waste into treasure since a mixture of 121 and 122 gave only 123.

P-Chiral Phosphorus Ligands and Enantioselective Synthesis of the Alkaloid (-)-Corynoline
As the field of asymmetric catalysis rapidly progresses, the search for new, efficient, and practical asymmetric catalytic transformations to facilitate the green synthesis of chiral natural products and drugs will continue to be a major ongoing effort in organic chemistry. Chiral phosphorus ligands...
ligands have played a significant role in recent advances in transition-metal-catalyzed asymmetric transformations. However, there are numerous challenging issues of reactivity and selectivity in catalysis. The development of new and efficient chiral phosphorus ligands with new structural motifs remains highly desirable. P-Chiral phosphorus ligands have been overlooked and are under development as most P-chiral phosphorus ligands are either difficult to prepare or operationally inconvenient. The development of efficient, practical, and operationally convenient P-chiral phosphorus ligands with new structural motifs remains an important subject of research.

Tang and his team of SIOC developed a series of efficient and practical P-chiral bis- and mono-phosphorus ligands (Scheme 27). Their unique structural and physical properties include P-chirality, conformational clarity, high tunability of electronic and steric properties, and operational simplicity as air-stable solids, making them exceptional ligands for several asymmetric catalytic reactions. With their powerful P-chiral phosphorus ligands, in 2018, a concise, five-step synthesis of acetyl cholinesterase inhibitor (-)-corynoline 139 from known indanone was achieved (Scheme 28), in which the key step is an enantioselective palladium-catalyzed α-arylation on the sterically hindered substrates. Next, radical dibromination at two benzylic positions gave dibromide, and treatment with methylamine then provided tertiary amine 137 in 37% yield over two steps. A subsequent marvelous Büchner–Curtius–Schlotterbeck reaction successfully converted the sterically hindered indanone into (-)-corynolon 138 in 56% yield.

Obviously, the construction of all-carbon quaternary centers is challenging due to the large steric effect, but it is also appealing. In particular, asymmetric catalytic methods

Scheme 27 Variety of P-chiral phosphorus ligands.

Scheme 28 The five-step route of enantioselective synthesis of (-)-corynoline.
applicable to the synthesis of chiral natural products and pharmaceutical molecules containing all-carbon quaternary centers remain in high demand. Although there has been a great deal of synthetic effort, efficient asymmetric syntheses, particularly those based on asymmetric catalytic methods, are still lacking. In this case, the chiral all-carbon quaternary center was constructed with the assistance of the bulky P-chiral ligand BI-DIME, which was efficient for various cross-coupling reactions of sterically hindered substrates (Scheme 29). The method is practical and highly efficient, featuring excellent enantioselectivities and good functional group compatibility with up to 98% yield and 99% ee values. This reaction is expected to be extensively applicable in drug discovery and process chemistry.67

Practical Asymmetric Synthesis of Chiral Cyclohexyl Spirobiindanes and Its Applications

Transition-metal-catalyzed asymmetric reactions are a hot issue and at the frontier of current organic chemistry research. Many of these chiral spiro ligands and related catalysts have not only shown high catalytic activity and high enantioselectivity for various asymmetrical reactions, but they have also made enantiocontrol of many catalytic asymmetric reactions, which are difficult in obtaining high enantioselectivities, easier and more feasible. Spiroketal-based diphosphine (SKP) ligands, developed by Ding’s group at SOIC, turned out to be the most appropriate and versatile ligands (Scheme 30).68

The chiral spiro skeleton has become a “privileged structure,” and chiral spiro ligands and catalysts have been used in the syntheses of different types of chiral compounds including chiral natural products and chiral drugs.69 For the synthesis of carbohydrates, which are polyhydroxylated compounds bearing multiple stereogenic centers, catalyst-directed stereoselective carbonyl addition in the absence of protecting groups has only been achieved using enzymes. In 2016, direct anomeric propargylation of unprotected aldoses with excellent levels of catalyst-directed diastereoselectivity was achieved (Scheme 31).70 The key features of anomeric propargylation is the chirality of the catalyst derived from the SKP skeleton, not the internal stereogenic centers of substrates, which predominantly controls the stereochemistry of the propargylation step.

Nickel Catalyst for Practical Asymmetric Hydrogenation of N-Sulfonyl Imines

Chiral amine compounds are important synthesis intermediates and have a wide range of applications in the synthesis of pharmaceuticals and fine chemicals. Asymmetric catalytic hydrogenation through imines is the most direct and efficient method of obtaining chiral amine compounds.71 In the past two decades, significant progress has been made in the asymmetric catalytic hydrogenation of imines. Various highly active, highly stereoselective chiral ligands and catalysts have been designed and synthesized,72 various new asymmetric catalytic methods and strategies have been developed and successfully applied, and important hydrogenation reactions of various special imine substrates have been important breakthroughs in pharmaceutical production. However, the asymmetric catalytic hydrogenation of N-sulfonyl imine still has low reactivity, a narrow substrate range, and harsh reaction conditions. Catalysts for these reactions are precious metals such as Rh, Ru, Ir, and Pd (compared with very cheap Ni), on the other hand, chiral ligands are also expensive; therefore, the development of a more economical, highly efficient, highly selective, and

Scheme 29 Pd(OAc)$_2$/BI-DIME catalyzed asymmetric α-arylation of sterically hindered substrates.

Scheme 30 Synthesis of chiral, aromatic spiroketals.
environmentally friendly asymmetric hydrogenation process or scale-up by the use of Ni is the future direction of asymmetric catalytic hydrogenation of imines.

Although hydrogenation reactions using chiral sulfenamides and N-tert-butanesulfinyl imines has been reported occasionally for more than a decade,73 these reactions all use quantitative chiral sulfenamides as the starting material, such as (R)- or (S)-tert-butanesulfinamide, which are clearly not atom economical. Furthermore, the catalyst is essentially a precious metal, such as Ru. The high loading of the catalyst indicates that it cannot comply with green-chemistry principles for sustainable development.

In 2001, it was reported that, in trifluoroethanol, fluorinated amino acids were prepared by Pd-catalyzed asymmetric hydrogenation of fluorinated iminoesters under the combined action of palladium and (R)-BINAP.74 In 2006, the palladium- and TangPhos-catalyzed hydrogenation of N-tosylimines also made progress,75 but it is not ideal for broad applications and for scale-up in terms of the high loading of Pd, cost of the chiral ligands, and the limit of general applicability, attributed to the low turnover number.

Chiral sulfonamides are common pharmacophores and are considered to be useful isosteres of carboxylic acids and carboxamides in drug discovery. In 2018, Zhou and coworkers developed a stepwise reductive amination of aryl ketones and the corresponding tosylamines via nickel-catalyzed asymmetric transfer hydrogenation (Scheme 32).76 Formic acid was used as a safe and economical surrogate of high-pressure hydrogen gas. As a result, a drug candidate 158 for the treatment of type II diabetes was effectively prepared.

In 2019, a breakthrough in the first asymmetric catalytic hydrogenation of N-sulfonyl imines catalyzed by an inexpensive metal, Ni (only 0.5 mol% loading), with chiral ligand (R,R)-QuinoxP was reported in Angewandte Chemie International Edition (Scheme 33). This paper was highlighted as a very important paper (VIP) and appeared as the cover story.77 The pioneering work performed by Zhang’s group involved a practical and robust transformation that has many advantages,

Scheme 31 Synthesis of sialic acids derivatives via (SKP-Cu)-catalyzed stereodivergent propargylation.

Scheme 32 Reductive amination of aryl ketones.
including excellent enantioselectivities, high conversion rates,
and amazingly high turnover numbers (S/C = 10,500 so far
when using Ni), all while using minimal (0.5 mol%) and the
cheapest nickel for asymmetric hydrogenation of prochiral N-
sulfonyl imines. We believe that this novel method will have
wider application in the near future for pharmaceutical pro-
cess development.

This excellent catalytic system is also suitable for three
types of cyclic N-sulfonyl imine substrates, including five- or
six-membered cyclic benzosultams which are important
bioactive molecules or drug candidates (Scheme 34).

It is worth noting that the t-Bu-sulfonyl groups could be
easily removed by using AlCl₃ to yield the corresponding
chiral amines in excellent conversion without loss of ee
(Scheme 35); nevertheless, we still hope a better deprotec-
tion method will be discovered in the future to make the
entire process more eco-friendly.

**Revolutionary Process of HMG-CoA Reductase
Inhibitors’ Side Chain**

Statins, as HMG-CoA reductase inhibitors, are a class of very
important drugs that regulate cholesterol biosynthesis, and
which have led to reduced risk of atherosclerosis and cardio-
vascular disease.

The pursuit of more potent statins uninter-
ruptedly continued at the level of these natural and synthetic
analouges, and, as a result of structural refinements, the third
generation of synthetic statins—the so-called superstatins—
represented by atorvastatin \[166\], rosuvastatin
\[169\], fluvastatin \[170\], and pitavastatin \[171\]—was developed
and launched on the market as more efficient hypolipidemic
drugs. In particular, atorvastatin \(168\) was the first pharma-
aceutical product to reach annual sales of 10 billion dollars, and
used to be the top-selling drug in the world. Structurally,
these synthetic superstatins commonly possess a pivotal syn-
1,3-diol moiety with two stereogenic centers, which attaches
to a heterocyclic core and poses an ongoing challenge for
economical and eco-friendly synthesis toward statin targets.

Obviously, central to the asymmetric synthesis of super-
statins is the construction of the crucial chiral side chain.
Continuous endeavors over more than 40 years have resulted
in the development of numerous strategies for stereoselective
generation of two stereocenters in the side chains of these
statins. The industrial approaches have mostly centered on
the manipulation of the chiral side chain \(175\) by well-estab-
lished diastereoselective Narasaka–Prasad reduction of chiral
β-hydroxy-3-ketoester \(7\) starting from readily available \(L\)-iso-
ascorbic acid \(172\) or \((S)\)-epichlorohydrin \((173;\) Scheme 36).

However, the major drawback of these large-scale syntheses
lies in utilizing toxic cyanide as C1-synthon for lateral chain
elongation.\(^{61,82}\)

Chen and coworkers designed a recyclable dimerization of
\((RR)\)-salen catalyst \([FDU-06–12\) catalyst \(177\)] to solve the
problem of constructing a C-3 stereocenter in the process of
chemical kinetic resolution \((176–178)\) and also discovered
the key technology of intramolecular diastereoselective oxida-
tive bromocyclization \((179–180)\) for C-5 stereocenter
formation.

**Scheme 33** Ni/(R,R)-QuinoxP⁺-catalyzed asymmetric catalytic hydrogenation of N-sulfonyl imines.

**Scheme 34** Ni/(R,R)-QuinoxP⁺-catalyzed asymmetric catalytic hydrogenation of cyclic N-sulfonyl imine.
Scheme 35 Removal of chiral auxiliary t-Bu-sulfonyl group.

Fig. 7 Representative superstatins.

Scheme 36 Outline of the industrial process of superstatins.
assembly (Scheme 37): in particular, this process could avoid the use of cyanide and greatly simplify the synthesis of the side chain and reduce costs. Then, Chen and coworkers achieved the efficient syntheses of atorvastatin (168), rosuvastatin (169), and pitavastatin (171). In 2014, Chen’s group accomplished an efficient asymmetric synthesis of atorvastatin (168) through a novel approach that involved an organocatalytic enantioselective cyclic anhydride desymmetrization to establish C-3 stereogenicity and a cyanide-free assembly of the C7 amino-type side chain via a C5þC2 strategy as the key transformations. Employing their developed bifunctional sulfonamide catalyst (Scheme 38), the enantioselective alcoholysis of 181 proceeded smoothly to deliver 183 in 93% yield and 90% ee. Subsequently, the cyanide-free installation of the C7 cyano-type side chain 184 occurred efficiently through a diethyl pyrocarbonate (DEPC)-promoted condensation of chiral hemiester 183 (C5 synthon) with methyl cyanoacetate (C2 synthon). The key C7 cyano-type side chain 184 was elaborated in several steps to amine 185, which could then be converted into atorvastatin (168) through a well-established sequence including a classical Paal–Knorr pyrrole approach. Furthermore, Chen’s group successfully developed a more streamlined approach to produce chiral syn-1,3-diol derivatives via asymmetric reduction strategies. Employing the NaBH4–L-tartaric acid system (Scheme 39), the prochiral ketone of readily available β-ketoester 186 can be reduced smoothly, to deliver the crucial enantioenriched homoallylic alcohols 187. This key transformation gives excellent control of the C-3 stereocenter (up to 86% yield, >99% ee) and places
other necessary functional groups in the right position. The subsequent quantitative esterification with (Boc)₂O led to ester 188, which was used in a diastereoselective oxidative bromocyclization protocol, affording syn-1,3-diol derivatives 189 in high yield (up to 94%), which have been proved powerfully useful as intermediates in the total syntheses of superstatins. In addition, Chen and coworkers recently developed a novel enzymatic strategy for producing the pivotal chiral homoallylic alcohols 187. As shown in Scheme 39, the biocatalytic approach involved the use of β-ketoester 186, which underwent bioreduction mediated by a ketoreductase (KRED) to afford the precursor of bromocyclization, homoallylic alcohols 187 in up to 88% yield with 99.9% ee. An isopropanol dehydrogenase served as a cofactor recycling enzyme in this process. The aforementioned efficient chemical/enzymatic reduction–bromocyclization strategy would be greatly beneficial to the scalable synthesis of superstatins.

Most recently, in the continuous consideration of the synthesis of the syn-1,3-diol moiety, Chen's group developed a one-pot diastereo-controlled synthesis of chiral syn-1,3-diol derivatives via CO₂ fixation/bromocyclization using in situ-generated ‘BuOBr in excellent yield and with both relative and absolute stereocontrol. As illustrated in Scheme 40, chiral homoallylic alcohol 190 was subjected to ‘BuOCl and NaBr under a continuously bubbling CO₂ system to generate the crucial bromocarbonate product 180 in 76% yield with >99% ee and >19:1 dr. Subsequently, a well-known three-step sequence afforded the general intermediate kaneka alcohol 191, which could then be readily transformed to superstatins, such as atorvastatin (168), rosuvastatin (169), and pitavastatin (171). Notably, this methodology is the first example of using CO₂ as

Scheme 39 Chen’s chemical and enzymatic reduction–bromocyclization approach.

Scheme 40 Chen’s bromocarboxylation approach using CO₂ as an oxygen source.
an oxygen source to construct chiral syn-1,3-diol moieties, as well as the most ideal synthesis of the essential structures, with excellent environmental protection potential and huge commercial value. This procedure was patented and successfully applied in the asymmetric synthesis of statins on a pilot plant scale in a pharmaceutical company.

Conclusions and Outlook

Pharmaceutical process chemistry is a complex and multidisciplinary field. Better and greener pharmaceutical process chemistry has many characteristics such as (i) the ability to choose cheap and readily available starting materials in large supply; (ii) use of inexpensive reagents, catalysts, and solvents; (iii) establishment of a reliable, speedy, and robust process for producing high-quality intermediates and APIs; (iv) an economical and convenient production method; (v) avoidance of high-risk operations and hazardous reagents; and (vi) use of safe and environmentally friendly operations and processes to reduce waste, including by-products, wastewater, and harmful gases. The above 12 case studies are representative of the outstanding achievements in developing greener pharmaceutical technologies and synthetic chemistries in the past two decades in China. In short, the green process has been a gradual and continuous development process, as there is no perfect process, but only a better process to innovate. Multiple improvements take time and contribute to the ultimate optimal process. The above cases show that the best comes later when one and more key transformations are greatly improved. The above cases also show that a well-chosen synthetic method and process can greatly improve the safety and economic benefit of the whole process, but only a better process to innovate. Multiple improvements take time and contribute to the ultimate optimal process. The above cases show that the best comes later when one and more key transformations are greatly improved.

China has a strong chemical foundation and it is a major producer of APIs and thousands of pharmaceutical intermediates. However, compared with advanced European and American pharmaceutical giants, there is still a certain gap in the Chinese pharmaceutical industry, especially in process development, as there still needs to be vigorous advocacy for new environmentally friendly green technologies. In recent years, people’s growing awareness of the importance of environmental protection has raised many challenges for China’s pharmaceutical R&D and production. Green pharmaceutical process is therefore an essential innovation for the healthy and sustainable development of the Chinese pharmaceutical industry. We also hope that Chinese chemists, whether in academia or in the industry, can better connect theory with empirical reality to tackle and truly solve the current challenges of pharmaceutical development and production for the betterment and protection of the environment and human health.

Conflict of Interest
The authors declare no conflicts of interest.

Acknowledgments
The authors are grateful for the support from the State Key Laboratory of Anti-Infective Drug Development (Sunshine Lake Pharma Co., Ltd; 2015DQ780357) and National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-year Plan Period (Grant No.2018ZX0921002–001). We are also grateful to Raymond Zhang at Cornell University for proofreading this manuscript.

References
1. Tan HL. China’s pharmaceutical industry is poised for major growth. Available at: https://www.cnbc.com/2018/04/19/chinas-pharmaceutical-industry-is-poised-for-major-growth.html. Accessed April 19, 2018


Recent Advances of Pharmaceutical Process Chemistry and Its Innovation in China  
Tang et al.  
Fronts  Vol. 2  No. 1/2020  